Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Intangibles (2016 - 2026)

Aytu Biopharma has reported Intangibles over the past 11 years, most recently at $43.6 million for Q4 2025.

  • Quarterly Intangibles fell 12.77% to $43.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.6 million through Dec 2025, down 12.77% year-over-year, with the annual reading at $42.2 million for FY2025, 40.95% down from the prior year.
  • Intangibles was $43.6 million for Q4 2025 at Aytu Biopharma, up from $41.4 million in the prior quarter.
  • Over five years, Intangibles peaked at $94.2 million in Q3 2021 and troughed at $30.2 million in Q1 2021.
  • The 5-year median for Intangibles is $64.2 million (2022), against an average of $64.6 million.
  • Year-over-year, Intangibles soared 785.6% in 2021 and then crashed 40.95% in 2025.
  • A 5-year view of Intangibles shows it stood at $94.2 million in 2021, then plummeted by 31.03% to $65.0 million in 2022, then dropped by 14.27% to $55.7 million in 2023, then fell by 10.33% to $50.0 million in 2024, then fell by 12.77% to $43.6 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Intangibles are $43.6 million (Q4 2025), $41.4 million (Q3 2025), and $42.2 million (Q2 2025).